Adamas Pharmaceuticals Inc (ADMS.OQ)
ADMS.OQ on NASDAQ Stock Exchange Global Market
27.43USD
2:22pm EDT
27.43USD
2:22pm EDT
Change (% chg)
$0.34 (+1.26%)
$0.34 (+1.26%)
Prev Close
$27.09
$27.09
Open
$27.08
$27.08
Day's High
$27.73
$27.73
Day's Low
$26.77
$26.77
Volume
97,363
97,363
Avg. Vol
221,496
221,496
52-wk High
$43.98
$43.98
52-wk Low
$13.51
$13.51
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -1.46 | December | 23 Jul 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 4 | 4 | 4 | 4 |
| (2) OUTPERFORM | 8 | 7 | 7 | 7 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.67 | 1.64 | 1.64 | 1.64 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 10 | 7.89 | 9.30 | 6.70 | 23.00 |
| Quarter Ending Dec-18 | 10 | 11.75 | 13.80 | 8.98 | 29.70 |
| Year Ending Dec-18 | 10 | 27.05 | 30.00 | 23.13 | 45.54 |
| Year Ending Dec-19 | 10 | 88.13 | 112.50 | 71.60 | 95.03 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 10 | -1.46 | -1.23 | -1.61 | -0.20 |
| Quarter Ending Dec-18 | 10 | -1.47 | -1.21 | -1.66 | 0.09 |
| Year Ending Dec-18 | 10 | -5.68 | -5.08 | -6.19 | -2.37 |
| Year Ending Dec-19 | 10 | -3.93 | -2.81 | -4.69 | -1.14 |
| LT Growth Rate (%) | 1 | 35.00 | 35.00 | 35.00 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 1.60 | 2.55 | 0.95 | 59.48 |
| Quarter Ending Dec-17 | 0.84 | 0.57 | 0.27 | 32.24 |
| Quarter Ending Sep-17 | 0.03 | 0.00 | 0.03 | 97.00 |
| Quarter Ending Jun-17 | 0.04 | 0.00 | 0.04 | 95.00 |
| Quarter Ending Mar-17 | 0.23 | 0.00 | 0.23 | 100.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | -1.37 | -1.35 | 0.02 | -1.73 |
| Quarter Ending Dec-17 | -1.18 | -1.27 | 0.09 | -7.73 |
| Quarter Ending Sep-17 | -0.98 | -1.04 | 0.06 | -6.48 |
| Quarter Ending Jun-17 | -0.81 | -0.93 | 0.12 | -15.28 |
| Quarter Ending Mar-17 | -0.71 | -0.72 | 0.01 | -1.88 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 7.89 | 7.89 | 7.89 | 7.89 | 23.00 |
| Quarter Ending Dec-18 | 11.75 | 11.97 | 11.97 | 11.97 | 29.70 |
| Year Ending Dec-18 | 27.05 | 27.24 | 27.24 | 27.24 | 45.54 |
| Year Ending Dec-19 | 88.13 | 88.55 | 88.55 | 88.55 | 95.03 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | -1.46 | -1.49 | -1.49 | -1.49 | -0.20 |
| Quarter Ending Dec-18 | -1.47 | -1.49 | -1.49 | -1.49 | 0.09 |
| Year Ending Dec-18 | -5.68 | -5.75 | -5.75 | -5.75 | -2.37 |
| Year Ending Dec-19 | -3.93 | -3.96 | -3.96 | -3.96 | -1.14 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri
- BRIEF-Adamas Announces First Patient Enrolled In Phase 3 Trial Of ADS 5102 In Multiple Sclerosis Patients With Walking Impairment
- BRIEF-Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia
- BRIEF-Adamas Pharmaceuticals Says As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
- BRIEF-Adamas Q4 Loss Per Share $1.27